201
|
Del Vecchio S, Zannetti A, Fonti R, Iommelli F, Pizzuti LM, Lettieri A, Salvatore M. PET/CT in cancer research: from preclinical to clinical applications. CONTRAST MEDIA & MOLECULAR IMAGING 2011; 5:190-200. [PMID: 20812287 DOI: 10.1002/cmmi.368] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
The identification of genetic and biochemical mechanisms underlying tumor growth and progression along with the unraveling of human genoma provided a plethora of new targets for cancer detection, treatment and monitoring. Simultaneously, the extraordinary development of a number of imaging technologies, including hybrid systems, allowed the visualization of biochemical, molecular and physiological aberrations linked to underlying mutations in a given tumor. In vivo evaluation of complex biological processes such as proliferation, apoptosis, angiogenesis, metastasis, gene expression, receptor-ligand interactions, transport of substrates and metabolism of nutrients in human cancers is feasible using PET/CT and radiolabeled molecular probes. Some of these compounds are in preclinical phases of evaluation whereas others have been already applied in clinical settings. Here we provide prominent examples on how some biological processes and target expression can be visualized by PET/CT in animal tumor models and cancer patients for the noninvasive detection of well-known markers of tumor aggressiveness, invasiveness and resistance to treatment and for the evaluation of tumor response to therapy.
Collapse
Affiliation(s)
- S Del Vecchio
- Department of Biomorphological and Functional Sciences, University of Naples Federico II, Naples, Italy.
| | | | | | | | | | | | | |
Collapse
|
202
|
Beyer T, Townsend DW, Czernin J, Freudenberg LS. The future of hybrid imaging-part 2: PET/CT. Insights Imaging 2011; 2:225-34. [PMID: 23099865 PMCID: PMC3288992 DOI: 10.1007/s13244-011-0069-4] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2010] [Revised: 11/14/2010] [Accepted: 01/13/2011] [Indexed: 11/28/2022] Open
Abstract
Since the 1990s, hybrid imaging by means of software and hardware image fusion alike allows the intrinsic combination of functional and anatomical image information. This review summarises the state-of-the-art of dual-modality imaging with a focus on clinical applications. We highlight selected areas for potential improvement of combined imaging technologies and new applications. In the second part, we briefly review the background of dual-modality PET/CT imaging, discuss its main applications and attempt to predict technological and methodological improvements of combined PET/CT imaging. After a decade of clinical evaluation, PET/CT will continue to have a significant impact on patient management, mainly in the area of oncological diseases. By adopting more innovative acquisition schemes and data processing PET/CT will become a fast and dose-efficient imaging method and an integral part of state-of-the-art clinical patient management.
Collapse
Affiliation(s)
- Thomas Beyer
- cmi-experts GmbH, Pestalozzistr. 3, 8032, Zürich, Switzerland,
| | | | | | | |
Collapse
|
203
|
Tixier F, Le Rest CC, Hatt M, Albarghach N, Pradier O, Metges JP, Corcos L, Visvikis D. Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med 2011; 52:369-78. [PMID: 21321270 DOI: 10.2967/jnumed.110.082404] [Citation(s) in RCA: 549] [Impact Index Per Article: 42.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
UNLABELLED (18)F-FDG PET is often used in clinical routine for diagnosis, staging, and response to therapy assessment or prediction. The standardized uptake value (SUV) in the primary or regional area is the most common quantitative measurement derived from PET images used for those purposes. The aim of this study was to propose and evaluate new parameters obtained by textural analysis of baseline PET scans for the prediction of therapy response in esophageal cancer. METHODS Forty-one patients with newly diagnosed esophageal cancer treated with combined radiochemotherapy were included in this study. All patients underwent pretreatment whole-body (18)F-FDG PET. Patients were treated with radiotherapy and alkylatinlike agents (5-fluorouracil-cisplatin or 5-fluorouracil-carboplatin). Patients were classified as nonresponders (progressive or stable disease), partial responders, or complete responders according to the Response Evaluation Criteria in Solid Tumors. Different image-derived indices obtained from the pretreatment PET tumor images were considered. These included usual indices such as maximum SUV, peak SUV, and mean SUV and a total of 38 features (such as entropy, size, and magnitude of local and global heterogeneous and homogeneous tumor regions) extracted from the 5 different textures considered. The capacity of each parameter to classify patients with respect to response to therapy was assessed using the Kruskal-Wallis test (P < 0.05). Specificity and sensitivity (including 95% confidence intervals) for each of the studied parameters were derived using receiver-operating-characteristic curves. RESULTS Relationships between pairs of voxels, characterizing local tumor metabolic nonuniformities, were able to significantly differentiate all 3 patient groups (P < 0.0006). Regional measures of tumor characteristics, such as size of nonuniform metabolic regions and corresponding intensity nonuniformities within these regions, were also significant factors for prediction of response to therapy (P = 0.0002). Receiver-operating-characteristic curve analysis showed that tumor textural analysis can provide nonresponder, partial-responder, and complete-responder patient identification with higher sensitivity (76%-92%) than any SUV measurement. CONCLUSION Textural features of tumor metabolic distribution extracted from baseline (18)F-FDG PET images allow for the best stratification of esophageal carcinoma patients in the context of therapy-response prediction.
Collapse
|
204
|
[18F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (PET/CT) Physiologic Imaging of Choroidal Melanoma: Before and After Ophthalmic Plaque Radiation Therapy. Int J Radiat Oncol Biol Phys 2011; 79:137-42. [DOI: 10.1016/j.ijrobp.2009.10.041] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2009] [Revised: 10/14/2009] [Accepted: 10/23/2009] [Indexed: 11/20/2022]
|
205
|
Abstract
Cellular energy metabolism is one of the main processes affected during the transition from normal to cancer cells, and it is a crucial determinant of cell proliferation or cell death. As a support for rapid proliferation, cancer cells choose to use glycolysis even in the presence of oxygen (Warburg effect) to fuel macromolecules for the synthesis of nucleotides, fatty acids, and amino acids for the accelerated mitosis, rather than fuel the tricarboxylic acid cycle and oxidative phosphorylation. Mitochondria biogenesis is also reprogrammed in cancer cells, and the destiny of those cells is determined by the balance between energy and macromolecule supplies, and the efficiency of buffering of the cumulative radical oxygen species. In glioblastoma, the most frequent and malignant adult brain tumor, a metabolic shift toward aerobic glycolysis is observed, with regulation by well known genes as integrants of oncogenic pathways such as phosphoinositide 3-kinase/protein kinase, MYC, and hypoxia regulated gene as hypoxia induced factor 1. The expression profile of a set of genes coding for glycolysis and the tricarboxylic acid cycle in glioblastoma cases confirms this metabolic switch. An understanding of how the main metabolic pathways are modified by cancer cells and the interactions between oncogenes and tumor suppressor genes with these pathways may enlighten new strategies in cancer therapy. In the present review, the main metabolic pathways are compared in normal and cancer cells, and key regulations by the main oncogenes and tumor suppressor genes are discussed. Potential therapeutic targets of the cancer energetic metabolism are enumerated, highlighting the astrocytomas, the most common brain cancer.
Collapse
|
206
|
De Ruysscher D, Faivre-Finn C, Nestle U, Hurkmans CW, Le Péchoux C, Price A, Senan S. European Organisation for Research and Treatment of Cancer Recommendations for Planning and Delivery of High-Dose, High-Precision Radiotherapy for Lung Cancer. J Clin Oncol 2010; 28:5301-10. [DOI: 10.1200/jco.2010.30.3271] [Citation(s) in RCA: 203] [Impact Index Per Article: 14.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
Purpose To derive recommendations for routine practice and clinical trials for techniques used in high-dose, high-precision thoracic radiotherapy for lung cancer. Methods A literature search was performed to identify published articles considered both clinically relevant and practical to use. Recommendations were categorized under the following headings: patient selection, patient positioning and immobilization, tumor motion, computed tomography and [18F]fluorodeoxyglucose–positron emission technology scanning, generating target volumes, radiotherapy treatment planning, treatment delivery, and scoring of response and toxicity. The American College of Chest Physicians grading of recommendations was used. Results Recommendations were identified for each of the recommendation categories. Although most of the recommended techniques have not been evaluated in multicenter clinical trials, their use in high-precision thoracic radiotherapy and stereotactic body radiotherapy (SBRT) appears to be justified on the basis of available evidence. Conclusion Recommendations to facilitate the clinical implementation of high-precision conformal radiotherapy and SBRT for lung tumors were identified from the literature. Some techniques that are considered investigational at present were also highlighted.
Collapse
Affiliation(s)
- Dirk De Ruysscher
- From the Maastricht University Medical Center, GROW Research Institute, Maastricht; Free University Medical Center, Amsterdam; and Catharina Hospital, Eindhoven, the Netherlands; the Christie, Manchester; and Edinburgh Cancer Centre, Western General Hospital, Edinburgh, United Kingdom; Freiburg University Medical Center, Freiburg, Germany; and Gustave Roussy Institute, Villejuif, France
| | - Corinne Faivre-Finn
- From the Maastricht University Medical Center, GROW Research Institute, Maastricht; Free University Medical Center, Amsterdam; and Catharina Hospital, Eindhoven, the Netherlands; the Christie, Manchester; and Edinburgh Cancer Centre, Western General Hospital, Edinburgh, United Kingdom; Freiburg University Medical Center, Freiburg, Germany; and Gustave Roussy Institute, Villejuif, France
| | - Ursula Nestle
- From the Maastricht University Medical Center, GROW Research Institute, Maastricht; Free University Medical Center, Amsterdam; and Catharina Hospital, Eindhoven, the Netherlands; the Christie, Manchester; and Edinburgh Cancer Centre, Western General Hospital, Edinburgh, United Kingdom; Freiburg University Medical Center, Freiburg, Germany; and Gustave Roussy Institute, Villejuif, France
| | - Coen W. Hurkmans
- From the Maastricht University Medical Center, GROW Research Institute, Maastricht; Free University Medical Center, Amsterdam; and Catharina Hospital, Eindhoven, the Netherlands; the Christie, Manchester; and Edinburgh Cancer Centre, Western General Hospital, Edinburgh, United Kingdom; Freiburg University Medical Center, Freiburg, Germany; and Gustave Roussy Institute, Villejuif, France
| | - Cécile Le Péchoux
- From the Maastricht University Medical Center, GROW Research Institute, Maastricht; Free University Medical Center, Amsterdam; and Catharina Hospital, Eindhoven, the Netherlands; the Christie, Manchester; and Edinburgh Cancer Centre, Western General Hospital, Edinburgh, United Kingdom; Freiburg University Medical Center, Freiburg, Germany; and Gustave Roussy Institute, Villejuif, France
| | - Allan Price
- From the Maastricht University Medical Center, GROW Research Institute, Maastricht; Free University Medical Center, Amsterdam; and Catharina Hospital, Eindhoven, the Netherlands; the Christie, Manchester; and Edinburgh Cancer Centre, Western General Hospital, Edinburgh, United Kingdom; Freiburg University Medical Center, Freiburg, Germany; and Gustave Roussy Institute, Villejuif, France
| | - Suresh Senan
- From the Maastricht University Medical Center, GROW Research Institute, Maastricht; Free University Medical Center, Amsterdam; and Catharina Hospital, Eindhoven, the Netherlands; the Christie, Manchester; and Edinburgh Cancer Centre, Western General Hospital, Edinburgh, United Kingdom; Freiburg University Medical Center, Freiburg, Germany; and Gustave Roussy Institute, Villejuif, France
| |
Collapse
|
207
|
Utility of fluorodeoxyglucose-positron emission tomography in the identification of new lesions in lung cancer patients for the assessment of therapy response. Nucl Med Commun 2010; 31:1008-15. [DOI: 10.1097/mnm.0b013e328340438d] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
208
|
Abstract
Imaging has become an indispensable tool in the study of cancer biology and in clinical prognosis and treatment. The rapid advances in high resolution fluorescent imaging at single cell level and MR/PET/CT image registration, combined with new molecular probes of cell types and metabolic states, will allow the physical scales imaged by each to be bridged. This holds the promise of translation of basic science insights at the single cell level to clinical application. In this article, we describe the recent advances in imaging at the macro- and micro-scale and how these advances are synergistic with new imaging agents, reporters, and labeling schemes. Examples of new insights derived from the different scales of imaging and relevant probes are discussed in the context of cancer progression and metastasis.
Collapse
Affiliation(s)
- John Condeelis
- Anatomy and Structural Biology, Gruss Lipper Biophotonics Center, Program in Microenvironment and Metastasis, Albert Einstein College of Medicine of Yeshiva University, Bronx, New York 10461, USA.
| | | |
Collapse
|
209
|
Unsuspected Synchronous Thyroid Carcinoma Revealed on a Post-Therapy F-18 FDG PET/CT, in a Patient With Follicular Lymphoma. Clin Nucl Med 2010; 35:879-81. [DOI: 10.1097/rlu.0b013e3181f49aa1] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
210
|
Abstract
OBJECTIVE There is growing interest in using PET/CT for evaluating early response to therapy in cancer treatment. Although widely available and convenient to use, standardized uptake value (SUV) measurements can be influenced by a variety of biologic and technologic factors. Many of these factors can be addressed with close attention to detail and appropriate quality control. This article will review factors potentially affecting SUV measurements and provide recommendations on ways to minimize when using serial PET to assess early response to therapy. CONCLUSION Scanner and reconstruction parameters can significantly affect SUV measurements. When using serial SUV measurements to assess early response to therapy, imaging should be performed on the same scanner using the same image acquisition and reconstruction protocols. In addition, attention to detail is required for accurate determination of the administered radiopharmaceutical dose.
Collapse
|
211
|
Salem N, Balkman JD, Wang J, Wilson DL, Lee Z, King CL, Basilion JP. In vivo imaging of schistosomes to assess disease burden using positron emission tomography (PET). PLoS Negl Trop Dis 2010; 4:e827. [PMID: 20877718 PMCID: PMC2943464 DOI: 10.1371/journal.pntd.0000827] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2009] [Accepted: 08/20/2010] [Indexed: 11/24/2022] Open
Abstract
BACKGROUND Schistosomes are chronic intravascular helminth parasites of humans causing a heavy burden of disease worldwide. Diagnosis of schistosomiasis currently requires the detection of schistosome eggs in the feces and urine of infected individuals. This method unreliably measures disease burden due to poor sensitivity and wide variances in egg shedding. In vivo imaging of schistosome parasites could potentially better assess disease burden, improve management of schistosomiasis, facilitate vaccine development, and enhance study of the parasite's biology. Schistosoma mansoni (S. mansoni) have a high metabolic demand for glucose. In this work we investigated whether the parasite burden in mice could be assessed by positron emission tomography (PET) imaging with 2-deoxy-2[(18)F]fluoro-D-glucose (FDG). METHODOLOGY/PRINCIPAL FINDINGS Live adult S. mansoni worms FDG uptake in vitro increased with the number of worms. Athymic nude mice infected with S. mansoni 5-6 weeks earlier were used in the imaging studies. Fluorescence molecular tomography (FMT) imaging with Prosense 680 was first performed. Accumulation of the imaging probe in the lower abdomen correlated with the number of worms in mice with low infection burden. The total FDG uptake in the common portal vein and/or regions of elevated FDG uptake in the liver linearly correlated to the number of worms recovered from infected animals (R(2) =0.58, P<0.001, n = 40). FDG uptake showed a stronger correlation with the worm burden in mice with more than 50 worms (R(2) = 0.85, P<0.001, n = 17). Cryomicrotome imaging confirmed that most of the worms in a mouse with a high infection burden were in the portal vein, but not in a mouse with a low infection burden. FDG uptake in recovered worms measured by well counting closely correlated with worm number (R(2) = 0.85, P<0.001, n = 21). Infected mice showed a 32% average decrease in total FDG uptake after three days of praziquantel treatment (P = 0.12). The total FDG uptake in untreated mice increased on average by 36% over the same period (P = 0.052). CONCLUSION FDG PET may be useful to non-invasively quantify the worm burden in schistosomiasis-infected animals. Future investigations aiming at minimizing non-specific FDG uptake and to improve the recovery of signal from worms located in the lower abdomen will include the development of more specific radiotracers.
Collapse
Affiliation(s)
- Nicolas Salem
- Department of Radiology, Case Western Reserve University, Cleveland, Ohio, United States of America
| | - Jason D. Balkman
- Department of Radiology, University Hospitals Case Medical Center, Cleveland, Ohio, United States of America
| | - Jing Wang
- Department of Radiology, Case Western Reserve University, Cleveland, Ohio, United States of America
| | - David L. Wilson
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, United States of America
| | - Zhenghong Lee
- Department of Radiology, University Hospitals Case Medical Center, Cleveland, Ohio, United States of America
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, United States of America
| | - Christopher L. King
- Center for Global Health and Disease, Case Western Reserve University, Cleveland, Ohio, United States of America
- Veterans Affairs Medical Center, Cleveland, Ohio, United States of America
| | - James P. Basilion
- Department of Radiology, Case Western Reserve University, Cleveland, Ohio, United States of America
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, United States of America
- NFCR Center for Molecular Imaging, Case Western Reserve University, Cleveland, Ohio, United States of America
| |
Collapse
|
212
|
Chiti A, Kirienko M, Grégoire V. Clinical use of PET-CT data for radiotherapy planning: what are we looking for? Radiother Oncol 2010; 96:277-9. [PMID: 20727607 DOI: 10.1016/j.radonc.2010.07.021] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2010] [Accepted: 07/29/2010] [Indexed: 11/15/2022]
|
213
|
Poisson T, Deandreis D, Leboulleux S, Bidault F, Bonniaud G, Baillot S, Aupérin A, Al Ghuzlan A, Travagli JP, Lumbroso J, Baudin E, Schlumberger M. 18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer. Eur J Nucl Med Mol Imaging 2010; 37:2277-85. [DOI: 10.1007/s00259-010-1570-6] [Citation(s) in RCA: 73] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2010] [Accepted: 07/12/2010] [Indexed: 11/30/2022]
|
214
|
Cerqueira MD, Allman KC, Ficaro EP, Hansen CL, Nichols KJ, Thompson RC, Van Decker WA, Yakovlevitch M. Recommendations for reducing radiation exposure in myocardial perfusion imaging. J Nucl Cardiol 2010; 17:709-18. [PMID: 20503120 DOI: 10.1007/s12350-010-9244-0] [Citation(s) in RCA: 242] [Impact Index Per Article: 17.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
|
215
|
Kobayashi H, Longmire MR, Ogawa M, Choyke PL, Kawamoto S. Multiplexed imaging in cancer diagnosis: applications and future advances. Lancet Oncol 2010; 11:589-95. [PMID: 20338808 PMCID: PMC3412687 DOI: 10.1016/s1470-2045(10)70009-7] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
The development of imaging technologies that have sufficient specificity and sensitivity to enable early, accurate detection of cancer and response to therapy has long been a goal in oncology. Various radiological techniques have been used for diagnosis and surveillance of disease recurrence and imaging has revolutionised oncology. However, despite the widespread use of technologies, the ability of currently available imaging methods to facilitate early detection, precise characterisation, and accurate localisation of malignant disease could be improved. The simultaneous use of two or more techniques, contrast reagents, signalling methods, or the coupling of agent and tissue properties to achieve so-called multiplexed imaging is a promising approach. In this review, we provide a broad overview of current and emerging multiplexed, imaging technologies.
Collapse
Affiliation(s)
- Hisataka Kobayashi
- Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1088, USA.
| | | | | | | | | |
Collapse
|
216
|
Wiant D, Gersh JA, Bennett M, Bourland JD. Evaluation of the spatial dependence of the point spread function in 2D PET image reconstruction using LOR-OSEM. Med Phys 2010; 37:1169-82. [PMID: 20384254 PMCID: PMC2837729 DOI: 10.1118/1.3310381] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
PURPOSE The use of positron emission tomography (PET) imaging has proved beneficial in the staging and diagnosis of several cancer disease sites. Additional applications of PET imaging in treatment planning and the evaluation of treatment response are limited by the relatively low spatial resolution of PET images. Including point spread function (PSF) information in the system matrix (SM) of iterative reconstruction techniques has been shown to produce improved spatial resolution in PET images. METHODS In this study, the authors sampled the spatially variant PSF at over 6000 locations in the field of view for a General Electric Discovery ST PET/CT (General Electric Healthcare, Waukesha, WI) scanner in 2D acquisition mode. The authors developed PSF blurred SMs based on different combinations of the radial, depth, and azimuthal spatial dependencies to test the overall spatial dependence of the PSF on image quality. The PSF blurred SMs were included in a LOR-OSEM reconstruction algorithm and used for image reconstruction of geometric phantoms. The authors also examined the effect of sampling density on PSF characterization to design a more efficient sampling scheme. RESULTS The authors found that depth dependent change in the amplitude of the detector response was the most important factor affecting image quality. A SM created from a PSF that introduced r (perpendicular to the LOR), d (parallel to the LOR), or r and d dependent blurring across the radial lines of response led to visually identifiable improvements in spatial resolution and contrast in reconstructed images compared to images reconstructed with a purely geometric SM with no PSF blurring. Images reconstructed using a SM with r and d dependent blurring across the radial lines of response showed improved spatial resolution and contrast-noise ratios compared to images reconstructed with a SM that had only r dependent blurring. Additionally, the authors determined that the PSF could be adequately characterized with roughly 85% fewer samples through the use of a better optimized sampling scheme. CONCLUSIONS PET image reconstruction using a SM made from an accurately characterized PSF that accounts for r and d dependencies results in improved spatial resolution and contrast-noise relations, which may aid in lesion boundary detection for treatment planning or quantitative assessment of treatment response.
Collapse
Affiliation(s)
- D Wiant
- Department of Radiation Oncology, School of Medicine, Wake Forest University, Winston-Salem, North Carolina 27157, USA.
| | | | | | | |
Collapse
|
217
|
Li XF, Ma Y, Sun X, Humm JL, Ling CC, O'Donoghue JA. High 18F-FDG uptake in microscopic peritoneal tumors requires physiologic hypoxia. J Nucl Med 2010; 51:632-8. [PMID: 20351353 DOI: 10.2967/jnumed.109.071233] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
UNLABELLED The objective of this study was to examine (18)F-FDG uptake in microscopic tumors grown intraperitoneally in nude mice and to relate this to physiologic hypoxia and glucose transporter-1 (GLUT-1) expression. METHODS Human colon cancer HT29 and HCT-8 cells were injected intraperitoneally into nude mice to generate disseminated tumors of varying sizes. After overnight fasting, animals, breathing either air or carbogen (95% O(2) + 5% CO(2)), were intravenously administered (18)F-FDG together with the hypoxia marker pimonidazole and cellular proliferation marker bromodeoxyuridine 1 h before sacrifice. Hoechst 33342, a perfusion marker, was administered 1 min before sacrifice. After sacrifice, the intratumoral distribution of (18)F-FDG was assessed by digital autoradiography of frozen tissue sections. Intratumoral distribution was compared with the distributions of pimonidazole, GLUT-1 expression, bromodeoxyuridine, and Hoechst 33342 as visualized by immunofluorescent microscopy. RESULTS Small tumors (diameter, <1 mm) had high (18)F-FDG accumulation and were severely hypoxic, with high GLUT-1 expression. Larger tumors (diameter, 1-4 mm) generally had low (18)F-FDG accumulation and were not significantly hypoxic, with low GLUT-1 expression. Carbogen breathing significantly decreased (18)F-FDG accumulation and tumor hypoxia in microscopic tumors but had little effect on GLUT-1 expression. CONCLUSION There was high (18)F-FDG uptake in microscopic tumors that was spatially associated with physiologic hypoxia and high GLUT-1 expression. This enhanced uptake was abrogated by carbogen breathing, indicating that in the absence of physiologic hypoxia, high GLUT-1 expression, by itself, was insufficient to ensure high (18)F-FDG uptake.
Collapse
Affiliation(s)
- Xiao-Feng Li
- Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
| | | | | | | | | | | |
Collapse
|
218
|
Identification of small molecule inhibitors of pyruvate kinase M2. Biochem Pharmacol 2009; 79:1118-24. [PMID: 20005212 DOI: 10.1016/j.bcp.2009.12.003] [Citation(s) in RCA: 186] [Impact Index Per Article: 12.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2009] [Revised: 12/02/2009] [Accepted: 12/03/2009] [Indexed: 12/12/2022]
Abstract
A common feature of tumors arising from diverse tissue types is a reliance on aerobic glycolysis for glucose metabolism. This metabolic difference between cancer cells and normal cells could be exploited for therapeutic benefit in patients. Cancer cells universally express the M2 isoform of the glycolytic enzyme pyruvate kinase (PKM2), and previous work has demonstrated that PKM2 expression is necessary for aerobic glycolysis and cell proliferation in vivo. Because most normal tissues express an isoform of pyruvate kinase other than PKM2, selective targeting of PKM2 provides an opportunity to target cell metabolism for cancer therapy. PKM2 has an identical catalytic site as the related M1 splice variant (PKM1). However, isoform selective inhibition is possible as PKM2 contains a unique region for allosteric regulation. We have screened a library of greater than 1,00,000 small molecules to identify such inhibitors. The inhibitors identified for PKM2 fell primarily into three distinct structural classes. The most potent PKM2 inhibitor resulted in decreased glycolysis and increased cell death following loss of growth factor signaling. At least part of this effect was due to on-target PKM2 inhibition as less cell death was observed in cells engineered to express PKM1. These data suggest that isoform selective inhibition of PKM2 with small molecules is feasible and support the hypothesis that inhibition of glucose metabolism in cancer cells is a viable strategy to treat human malignancy.
Collapse
|
219
|
Yang C, Sudderth J, Dang T, Bachoo RM, Bachoo RG, McDonald JG, DeBerardinis RJ. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res 2009; 69:7986-93. [PMID: 19826036 DOI: 10.1158/0008-5472.can-09-2266] [Citation(s) in RCA: 311] [Impact Index Per Article: 20.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Oncogenes influence nutrient metabolism and nutrient dependence. The oncogene c-Myc stimulates glutamine metabolism and renders cells dependent on glutamine to sustain viability ("glutamine addiction"), suggesting that treatments targeting glutamine metabolism might selectively kill c-Myc-transformed tumor cells. However, many current or proposed cancer therapies interfere with the metabolism of glucose, not glutamine. Here, we studied how c-Myc-transformed cells maintained viability when glucose metabolism was impaired. In SF188 glioblastoma cells, glucose deprivation did not affect net glutamine utilization but elicited a switch in the pathways used to deliver glutamine carbon to the tricarboxylic acid cycle, with a large increase in the activity of glutamate dehydrogenase (GDH). The effect on GDH resulted from the loss of glycolysis because it could be mimicked with the glycolytic inhibitor 2-deoxyglucose and reversed with a pyruvate analogue. Furthermore, inhibition of Akt signaling, which facilitates glycolysis, increased GDH activity whereas overexpression of Akt suppressed it, suggesting that Akt indirectly regulates GDH through its effects on glucose metabolism. Suppression of GDH activity with RNA interference or an inhibitor showed that the enzyme is dispensable in cells able to metabolize glucose but is required for cells to survive impairments of glycolysis brought about by glucose deprivation, 2-deoxyglucose, or Akt inhibition. Thus, inhibition of GDH converted these glutamine-addicted cells to glucose-addicted cells. The findings emphasize the integration of glucose metabolism, glutamine metabolism, and oncogenic signaling in glioblastoma cells and suggest that exploiting compensatory pathways of glutamine metabolism can improve the efficacy of cancer treatments that impair glucose utilization.
Collapse
Affiliation(s)
- Chendong Yang
- Department of Pediatrics, McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center at Dallas, Texas 75390-9063, USA
| | | | | | | | | | | | | |
Collapse
|
220
|
Bjurberg M, Henriksson E, Brun E, Ekblad L, Ohlsson T, Brun A, Kjellén E. Early changes in 2-deoxy-2-[18F]fluoro-D-glucose metabolism in squamous-cell carcinoma during chemotherapy in vivo and in vitro. Cancer Biother Radiopharm 2009; 24:327-32. [PMID: 19538055 DOI: 10.1089/cbr.2008.0556] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
AIM The aim of this study was to investigate early changes in uptake of 2-deoxy-2-[(18)F]fluoro-D-glucose (FDG) in vivo and in vitro in a squamous-cell carcinoma (SCC) cell line originating from a human head and neck SCC during cytotoxic therapy with respect to metabolism in tumor cells and in surrounding stromal tissue. MATERIALS AND METHODS In 60 nude mice with xenografted SCC, 50 animals were treated with cisplatin. Early changes in the tumor FDG uptake following therapy were evaluated sequentially with phosphor imaging. Using this technique, areas with focal hypermetabolism were detected. The cells creating the focal hypermetabolism were then identified histopathologically on the corresponding sections. In addition, early FDG uptake versus the number of viable tumor cells was measured in vitro following cisplatin treatment. RESULTS An early transient increase in FDG uptake in tumor cells was seen on day 1 in treated tumors, followed by a rapid decrease confirmed by subsequent tumor regression. This metabolic flare was present in all treated tumors but not in the controls. In vitro, an increase in FDG uptake per cell was observed. CONCLUSIONS Our results provide new insights into the early metabolic changes in squamous-cell carcinomas subjected to cytotoxic therapy and thus contribute to the discussion on the feasibility of early predictive PET studies.
Collapse
Affiliation(s)
- Maria Bjurberg
- Department of Oncology, Lund University Hospital, Lund, Sweden.
| | | | | | | | | | | | | |
Collapse
|
221
|
Nichols KJ, Van Tosh A, Palestro CJ. Prospects for advancing nuclear cardiology by means of new detector designs. J Nucl Cardiol 2009; 16:691-6. [PMID: 19629610 DOI: 10.1007/s12350-009-9123-8] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2009] [Accepted: 07/06/2009] [Indexed: 10/20/2022]
|
222
|
|
223
|
Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324:1029-33. [PMID: 19460998 PMCID: PMC2849637 DOI: 10.1126/science.1160809] [Citation(s) in RCA: 10899] [Impact Index Per Article: 726.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
In contrast to normal differentiated cells, which rely primarily on mitochondrial oxidative phosphorylation to generate the energy needed for cellular processes, most cancer cells instead rely on aerobic glycolysis, a phenomenon termed "the Warburg effect." Aerobic glycolysis is an inefficient way to generate adenosine 5'-triphosphate (ATP), however, and the advantage it confers to cancer cells has been unclear. Here we propose that the metabolism of cancer cells, and indeed all proliferating cells, is adapted to facilitate the uptake and incorporation of nutrients into the biomass (e.g., nucleotides, amino acids, and lipids) needed to produce a new cell. Supporting this idea are recent studies showing that (i) several signaling pathways implicated in cell proliferation also regulate metabolic pathways that incorporate nutrients into biomass; and that (ii) certain cancer-associated mutations enable cancer cells to acquire and metabolize nutrients in a manner conducive to proliferation rather than efficient ATP production. A better understanding of the mechanistic links between cellular metabolism and growth control may ultimately lead to better treatments for human cancer.
Collapse
Affiliation(s)
- Matthew G. Vander Heiden
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
- Beth-Israel Deaconess Cancer Center and Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA
| | - Lewis C. Cantley
- Beth-Israel Deaconess Cancer Center and Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA
| | - Craig B. Thompson
- Department of Cancer Biology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA
| |
Collapse
|
224
|
Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. SCIENCE (NEW YORK, N.Y.) 2009. [PMID: 19460998 DOI: 10.1126/science.1160809] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
In contrast to normal differentiated cells, which rely primarily on mitochondrial oxidative phosphorylation to generate the energy needed for cellular processes, most cancer cells instead rely on aerobic glycolysis, a phenomenon termed "the Warburg effect." Aerobic glycolysis is an inefficient way to generate adenosine 5'-triphosphate (ATP), however, and the advantage it confers to cancer cells has been unclear. Here we propose that the metabolism of cancer cells, and indeed all proliferating cells, is adapted to facilitate the uptake and incorporation of nutrients into the biomass (e.g., nucleotides, amino acids, and lipids) needed to produce a new cell. Supporting this idea are recent studies showing that (i) several signaling pathways implicated in cell proliferation also regulate metabolic pathways that incorporate nutrients into biomass; and that (ii) certain cancer-associated mutations enable cancer cells to acquire and metabolize nutrients in a manner conducive to proliferation rather than efficient ATP production. A better understanding of the mechanistic links between cellular metabolism and growth control may ultimately lead to better treatments for human cancer.
Collapse
|